Previously dba - and SBIR Involved - as MedaSorb Technologies Corporation (OTCBB: MSBT), in 2010 the firm was renamed CytoSorbents Corporation (NASDAQ:CTSO): a therapeutic medical device company involved in development of medical devices utilizing its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, a cartridge containing adsorbent polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. CytoSorbents Corporation?s CytoSorb device is designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company?s products also include BetaSorb device that utilizes an adsorbent polymer packed into a cartridge and incorporates connectors at either end of the device to connect directly into the extra-corporeal circuit in series with a dialyzer. Its BetaSorb is designed to prevent and treat health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure. The company also develops hemodefend blood purification technology to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients. Originally known as MedaSorb Technologies Corporation, the firm changed its name to CytoSorbents Corporation in May 2010. Moved to OTC
